Risk of Diabetes Mellitus in Persons with and without HIV: A Danish Nationwide Population-Based Cohort Study

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Rasmussen, Line D ^a   Mathiesen, Elisabeth R ^b   Kronborg, Gitte ^c   Pedersen, Court ^a   Gerstoft, Jan ^b   Obel, Niels ^b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^c NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; DIDANOSINE; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DANISH; DIABETES MELLITUS; DRUG EXPOSURE; ETHNIC GROUP; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; RISK ASSESSMENT; SEX DIFFERENCE;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY MASS INDEX; COHORT STUDIES; DENMARK; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIDANOSINE; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; INDINAVIR; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RISK FACTORS; SAQUINAVIR; STAVUDINE; TREATMENT OUTCOME;

EID: 84866324585     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044575     Document Type: Article

References (37)

1. Calza L, Manfredi R, Chiodo F, (2004) Insulin resistance and diabetes mellitus in HIV-infected patients receiving antiretroviral therapy. Metab Syndr Relat Disord. 2: 241-250.
2. Grinspoon S, (2003) Mechanisms and strategies for insulin resistance in acquired immune deficiency syndrome. Clin Infect Dis. 37: 85-90.
3. Safrin S, Grunfeld C, (1999) Fat distribution and metabolic changes in patients with HIV infection. AIDS. 13: 2493-2505.
4. Antiretroviral Therapy Cohort collaboration, (2008) Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 372: 293-299.
5. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, et al. (2007) Survival of persons with and without HIV infection in Denmark 1995-2005. Ann Intern Med. 146: 87-95.
6. Glümer C, Carstensen B, Sandbaek A, Lauritzen T, Jørgensen T, et al. (2004) A Danish diabetes risk score for targeted screening: the Inter99 study. Diabetes care. 27: 727-733.
7. Ledergerber B, Furrer H, Rickenbach M, Lehmann R, Elzi L, et al. (2007) Swiss HIV Cohort Study. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis. 45: 111-119.
8. Butt AA, McGinnis K, Rodriguez-Barradas MC, Crystal S, Simberkoff M, et al. (2009) Veterans Aging Cohort Study. HIV infection and the risk of diabetes mellitus. AIDS. 23: 1227-1234.
9. De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, et al. (2008) Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. Diabetes Care. 31: 1224-1229.
10. Lo YC, Chen MY, Sheng WH, Hsieh SM, Sun HY, et al. (2009) Risk factors for incident diabetes mellitus among HIV-infected patients receiving combination antiretroviral therapy in Taiwan: a case-control study. HIV Med. 10: 302-309.
11. Brambilla AM, Novati R, Calori G, Meneghini E, Vachini D, et al. (2003) Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals. AIDS. 17: 1993-1995.
12. Visnegarwala F, Chen L, Raghavan S, Tedaldi E, (2005) Prevalence of diabetes mellitus and dyslipidemia among antiretroviral naïve patients co-infected with hepatitis C virus (HCV) and HIV-1 compared to patients without co-infection. J Infect. 50: 331-337.
13. Howard AA, Hoover DR, Anastos K, Wu X, Shi Q, et al. (2010) The effects of opiate use and hepatitis C virus infection on risk of diabetes mellitus in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr. 54: 152-159.
14. Lumpkin MM (1997) Reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus (HIV). FDA Public Health Advisory, June 21.
15. Dubé MP, Johnson DL, Currier JS, Leedom JM, (1997) Protease inhibitor-associated hyperglycemia. Lancet. 350: 713-714.
16. Walli R, Herfort O, Michl GM, Demant T, Jäger H, et al. (1998) Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS. 12: F167-F173.
17. Tsiodras S, Mantzoros C, Hammer S, Samore M, (2000) Effects of protease inhibitors on hyperglycemia, hyperlipidemia and lipodystrophy: a 5 year-cohort study. Arch Intern Med. 160: 2050-2056.
18. Justman JE, Benning L, Danoff A, Minkoff H, Levine A, et al. (2003) Protease Inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr. 32: 298-302.
19. Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, et al. (2005) Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 165: 1179-1184.
20. Brown TT, Li X, Cole SR, Kingsley LA, Palella FJ, et al. (2005) Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS. 19: 1375-1383.
21. Tien PC, Schneider MF, Cole SR, Levine AM, Cohen M, et al. (2007) Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS. 21: 1739-1745.
22. Capeau J, Bouteloup V, Katlama C, Bastard JP, Guiyedi V,et al; ANRS CO8 APROCO-COPILOTE Cohort Study Group (2012) Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. AIDS. 26: 303-314.
23. Polsky S, Floris-Moore M, Schoenbaum EE, Klein RS, Arnsten JH, et al. (2011) Incident hyperglycemia among older adults with or at risk for HIV infection. Antivir Ther. 16: 181-188.
24. Idiculla J, Ravindra'n GD, D'Souza J, Singh G, Furruqh S, (2011) Diabetes mellitus, insulin resistance, and metabolic syndrome in HIV-positive patients in South India. Int J Gen Med. 4: 73-78.
25. Statistics Denmark. Population and Election. Available: http://www.dst.dk/HomeUK/Statistics/Key_indicators/Population/pop.aspx. Accessed 2011 Oct 9.
26. Lohse N, Hansen AB, Jensen-Fangel S, Kronborg G, Kvinesdal B, et al. (2005) Demographics of HIV-1 infection in Denmark: results from the Danish HIV Cohort Study. Scand J Infect Dis. 37: 338-343.
27. Obel N, Engsig FN, Rasmussen LD, Larsen MV, Omland LH, et al. (2009) Cohort profile: the Danish HIV Cohort Study. Int J Epidemol. 38: 1202-1206.
28. Pedersen CB, (2011) The Danish Civil Registration System. Scan J Pub Health. 39: 22-25.
29. Andersen TF, Madsen M, Jørgensen J, Mellemkjoer L, Olsen JH, (1999) The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull. 46: 263-268.
30. Kiledemoes HW, Sørensen HT, Hallas J, (2011) The Danish National Prescription Registry. Scan J Public Health. 39: 38-41.
31. Petersen I, Nielsen MM, Beck-Nielsen H, Christensen K, (2011) No evidence of a higher 10 year period prevalence of diabetes among 77,885 twins compared with 215,264 singletons from the Danish birth cohorts 1910-1989. Diabetologica. 54: 2016-2024.
32. Harris MI, (1991) Epidemiological correlates of NIDDM in Hispanics, whites, and blacks in the U.S. population. Diabetes care. 14: 639-648.
33. Hommel K, Rasmussen S, Madsen M, Kamper AL, (2010) The Danish Registry on Regular Dialysis and Transplantation: completeness and validity of incident patient registration. Nephrol Dial Transplant. 25: 947-951.
34. Danoff A, Justman J, Mulligan K, Hessol N, Robinson E, et al. (2005) Oral glucose tolerance and insulin sensitivity are unaffected by HIV infection or antiretroviral therapy in overweight women. J Acquir Immune Defic Syndr. 39: 55-62.
35. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, et al. (2001) The continuing epidemics of obesity and diabetes in the United States. JAMA. 286: 1195-1200.
36. Noor MA, Lo JC, Mulligan K, Schwarz JM, Halvorsen RA, et al. (2001) Metabolic effects of indinavir in healthy HIV seronegative men. AIDS. 15: F11-18.
37. Noor MA, Seneviratne T, Aweeka FT, Lo JC, Schwarz JM, et al. (2002) Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: A randomized, placebo-controlled study. AIDS. 16: F1-8.